Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of BEZ235 versus everolimus in advanced pancreatic neuroendocrine tumors
NL-OMON40098Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in islet cell tumor comparing BEZ235 with everolimus (2 arms). Primary endpoint: Progression-free survival. Started Apr 2013; status: active, not recruiting.
02
Drugs
dactolisibeverolimus
03
Conditions
islet cell tumor
Beyond the preview
Go deeper on NL-OMON40098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40098.